By Ni Zhenhua King & Wood Mallesons’ IP group.
The exemplary case of SAP SE
SAP SE (the Plaintiff), founded in 1972 and headquartered in Walldorf, Germany, is the largest provider of enterprise management and collaborative commercial solutions in the world. It is also the world’s third largest independent software supplier, with more than 102,500 enterprises in 120 countries worldwide using SAP software and over 80% of Fortune 500 enterprises benefiting from its management solutions. In the 1980s, SAP SE entered the Chinese market. Thanks to its successful operation over three decades, it has won great recognition in China. Continue Reading Protecting foreign copyright in China: how is compensation for damages calculated?


With the Belt and Road initiative likely to drive significant outbound investment by Chinese companies, the ability to enforce foreign arbitral awards in the People’s Republic of China (PRC) will be a key issue for these companies and their Belt and Road counterparties.
近日,国务院办公厅印发了关于《深化医药卫生体制改革2017年重点工作任务》的通知 [1],提出“2017年是贯彻落实全国卫生与健康大会精神和实施“十三五”深化医药卫生体制改革规划的重要一年,是形成较为系统的基本医疗卫生制度框架、完成医改阶段性目标任务的关键一年” 。近两年来,医药改革在定价、流通及采购环节均实施了一些新的政策,其中对于医药企业商业模式影响较大的包括以下内容: